Metraipolis › archive › dc_3debee4db64f

Three-Year Outcomes of Neoadjuvant Chemoimmunotherapy vs. Neoadjuvant Chemoradiotherapy in Resectable Esophageal Cancer: A Multicenter Retrospective Study — Europe PMC PMID:41514663

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41514663
DOI: 10.3390/cancers18010155
License (as archived): solo-consultazione
Archived: 2026-11-07T03:47:53.416Z
SHA-256 of the archived text: d5cc0e19fb55165259f800cf01f311e451249cc41d3a65ce408400dc511a780e
Stable URL of this page: https://metraipolis.com/documento/dc_3debee4db64f

How to cite

Three-Year Outcomes of Neoadjuvant Chemoimmunotherapy vs. Neoadjuvant Chemoradiotherapy in Resectable Esophageal Cancer: A Multicenter Retrospective Study — Europe PMC PMID:41514663 — Europe PMC (en), https://europepmc.org/article/MED/41514663 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_3debee4db64f (Metraipolis archive dc_3debee4db64f, sha256 d5cc0e19fb55165259f800cf01f311e451249cc41d3a65ce408400dc511a780e)

BibTeX

@misc{dc3debee4db64f,
  title = {Three-Year Outcomes of Neoadjuvant Chemoimmunotherapy vs. Neoadjuvant Chemoradiotherapy in Resectable Esophageal Cancer: A Multicenter Retrospective Study — Europe PMC PMID:41514663},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41514663},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_3debee4db64f; sha256 d5cc0e19fb55165259f800cf01f311e451249cc41d3a65ce408400dc511a780e},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41514663. Agents can read the archived copy with the MCP tool read_document.